GSK announced on Thursday that its subsidiary ViiV Healthcare has received approval from China’s National Medical Products Administration for ‘Vocabria’, or cabotegravir, injection in combination with Janssen’s ‘Rekambys’ for treating HIV-1 in adults. The approval followed the prior authorisation of cabotegravir injection and tablets in China in July. It said the combination therapy was an alternative to daily oral medication for people with HIV-1 and addressed potential adherence challenges, given that more than one million people were living with HIV in China as of October 2020.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments